EP Wealth Advisors LLC Buys New Position in IQVIA Holdings Inc. (NYSE:IQV)

EP Wealth Advisors LLC bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,050 shares of the medical research company’s stock, valued at approximately $354,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. FMR LLC raised its holdings in shares of IQVIA by 24.7% during the first quarter. FMR LLC now owns 5,620,968 shares of the medical research company’s stock valued at $1,117,954,000 after acquiring an additional 1,111,803 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of IQVIA by 2.2% during the first quarter. Geode Capital Management LLC now owns 3,804,161 shares of the medical research company’s stock valued at $754,864,000 after acquiring an additional 81,501 shares in the last quarter. Lazard Asset Management LLC grew its stake in IQVIA by 1.0% in the fourth quarter. Lazard Asset Management LLC now owns 2,844,533 shares of the medical research company’s stock worth $582,814,000 after purchasing an additional 29,537 shares during the period. Longview Partners Guernsey LTD grew its stake in IQVIA by 9.4% in the first quarter. Longview Partners Guernsey LTD now owns 2,707,910 shares of the medical research company’s stock worth $538,576,000 after purchasing an additional 232,872 shares during the period. Finally, Amundi grew its stake in IQVIA by 0.6% in the fourth quarter. Amundi now owns 2,230,818 shares of the medical research company’s stock worth $494,193,000 after purchasing an additional 13,947 shares during the period. Institutional investors own 86.82% of the company’s stock.

IQVIA Stock Down 0.6 %

IQV stock opened at $211.71 on Monday. IQVIA Holdings Inc. has a fifty-two week low of $165.75 and a fifty-two week high of $241.86. The business’s 50-day moving average is $220.12 and its two-hundred day moving average is $208.08. The company has a debt-to-equity ratio of 2.16, a quick ratio of 0.81 and a current ratio of 0.81. The company has a market cap of $38.77 billion, a price-to-earnings ratio of 36.44, a P/E/G ratio of 2.15 and a beta of 1.37.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, August 1st. The medical research company reported $2.22 earnings per share for the quarter, beating analysts’ consensus estimates of $2.09 by $0.13. IQVIA had a return on equity of 30.14% and a net margin of 7.47%. The company had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.70 billion. As a group, analysts forecast that IQVIA Holdings Inc. will post 9.24 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Stifel Nicolaus upped their price target on IQVIA from $255.00 to $281.00 and gave the stock a “buy” rating in a research note on Wednesday, August 2nd. Truist Financial upped their price target on IQVIA from $244.00 to $260.00 and gave the stock a “buy” rating in a research note on Tuesday, July 18th. Barclays upped their price target on IQVIA from $230.00 to $250.00 in a research note on Tuesday, June 27th. StockNews.com initiated coverage on IQVIA in a research note on Thursday, August 17th. They issued a “hold” rating on the stock. Finally, Citigroup increased their target price on IQVIA from $200.00 to $225.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $252.00.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.